Celularity, Inc. (NASDAQ:CELU) Short Interest Up 370.2% in August

Celularity, Inc. (NASDAQ:CELU) saw a large growth in short interest during the month of August. As of August 31st, there was short interest totaling 1,897,722 shares, a growth of 370.2% from the August 15th total of 403,568 shares. Approximately 7.9% of the shares of the stock are sold short. Based on an average daily volume of 21,797,628 shares, the short-interest ratio is presently 0.1 days.

Institutional Trading of Celularity

Institutional investors have recently made changes to their positions in the stock. C V Starr & Co. Inc. acquired a new position in Celularity in the 2nd quarter valued at approximately $1,582,000. XTX Topco Ltd purchased a new position in shares of Celularity during the 4th quarter valued at $33,000. Jane Street Group LLC acquired a new position in shares of Celularity in the fourth quarter worth $46,000. Geode Capital Management LLC raised its holdings in shares of Celularity by 15.0% during the fourth quarter. Geode Capital Management LLC now owns 160,190 shares of the company’s stock worth $178,000 after acquiring an additional 20,876 shares in the last quarter. Finally, Vanguard Group Inc. boosted its position in Celularity by 35.3% during the third quarter. Vanguard Group Inc. now owns 676,650 shares of the company’s stock valued at $1,401,000 after purchasing an additional 176,518 shares during the last quarter. 19.02% of the stock is currently owned by institutional investors and hedge funds.

Celularity Stock Performance

NASDAQ:CELU traded down $0.02 during trading hours on Friday, hitting $1.42. 76,866 shares of the company’s stock traded hands, compared to its average volume of 1,524,144. The stock’s fifty day moving average price is $0.95 and its two-hundred day moving average price is $1.01. The firm has a market cap of $40.96 million, a P/E ratio of -0.42 and a beta of 0.79. Celularity has a twelve month low of $0.56 and a twelve month high of $2.55.

Analyst Ratings Changes

Separately, Weiss Ratings raised Celularity from a “sell (e+)” rating to a “sell (d-)” rating in a report on Thursday, August 27th. One equities research analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the stock currently has a consensus rating of “Sell”.

Celularity Company Profile

Celularity, Inc is a clinical-stage biotechnology company focused on the development of allogeneic, placenta-derived cell therapies and exosome-based biologics for oncology, regenerative medicine and immune-driven conditions. Utilizing a proprietary platform that harnesses the unique properties of postpartum placental cells, the company aims to create off-the-shelf therapies that can be administered without the need for tissue matching or conditioning regimens.

The company’s pipeline includes a range of natural killer (NK) cell products, mesenchymal-like placental stromal cells and exosome formulations designed to modulate inflammatory responses and target tumor cells.